Evidence map›Paper›PMID 38784189›Full record

ArticleObstetric medicine2024

Management of fetal hyperthyroidism caused by persistent autoimmune antibodies in a case of previously treated maternal Graves' disease.

Susmita Reddy Karri, Priya Susan Roy, Nirjhar Nandi, Vasant Shenoy, David Watson

Abstract read
In one paragraph

Article in Obstetric medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Susmita Reddy KarriDepartment of Endocrinology, Townsville University Hospital, Douglas, Australia.ORCID https://orcid.org/0000-0001-8587-8581
Priya Susan RoyGenetic Pathology, Pathology Queensland, Brisbane, Australia.
Nirjhar NandiDepartment of Endocrinology, Cairns Hospital, Cairns, Australia.
Vasant ShenoyDepartment of Endocrinology, Townsville University Hospital, Douglas, Australia.
David WatsonJames Cook University, Townsville, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Maternal Graves' autoantibodies are well known to cause fetal and neonatal thyroid disturbances. Despite radioiodine therapy, Graves' autoantibodies are known to persist, which can cross the placenta and cause hyperthyroidism in the fetus. We present the case of a 26-year-old woman in her first pregnancy, clinically and biochemically euthyroid with history of treated Graves' disease, where the fetus showed signs of hyperthyroidism on antenatal scans. This was confirmed by amniotic fluid testing as fetal blood sampling was not feasible and successfully treated with maternal carbimazole whilst continuing thyroxine for the mother (block-replacement). We discuss the challenges in the diagnosis of fetal hyperthyroidism and treatment whilst maternal thyroid status is maintained on thyroxine.

Indexed as

fetal hyperthyroidismgoitreGraves’ diseasepregnancyradioactive iodinethyroid-stimulating immunoglobulin

Identifiers

PMID38784189
PMCPMC11110752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.